Tyrosine kinase inhibitors for the frontline management of CML: an overview


  • Dennis Dong Hwan Kim, MD, PhD




The introduction of Tyrosine Kinase Inhibitors (TKI) for the treatment of chronic myeloid leukemia (CML) has revolutionized CML therapy. These agents have increased the life expectancy of CML patients to 98% of those in the general population. Since the first approval of imatinib for CML treatment (by the US FDA in 2001), three additional TKIs have been approved for the indication of frontline therapy in CML during chronic phase (CP), including: dasatinib, nilotinib and bosutinib. This article will discuss the initial steps for newly diagnosed CML patients, its frontline therapy, and its management.

Author Biography

Dennis Dong Hwan Kim, MD, PhD

Dr. Dennis Kim is a clinician investigator at Princess Margaret Cancer Centre in Toronto. His research focuses on biomarker discovery using genomics in leukemias and allogeneic stem cell transplantation and chronic myeloid leukemia and graft-versus-host disease after allogeneic stem cell transplantation. He has been involved in multiple exome sequencing projects in acute myeloid leukemia (AML) with normal karyotype and secondary AML progressed from antecedent hematologic malignancies, as well as chronic myeloid leukemia (CML). The future direction of his genomic research involves the integration of multi-omics platforms to investigate leukemia genomes, thus dissecting clonal structures in a refined way. He has been involved in multiple clinical trials and is currently the principal investigator of a pivotal Canadian tyrosine kinase inhibitor (TKI) discontinuation clinical trial.


Bower H, Bjorkholm M, Dickman PW, Hoglund M, Lambert PC, Andersson TM. Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population. J Clin Oncol. 2016;34(24):2851-2857. DOI: https://doi.org/10.1200/JCO.2015.66.2866

O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994-1004. DOI: https://doi.org/10.1056/NEJMoa022457

Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362(24):2260-2270. DOI: https://doi.org/10.1056/NEJMoa1002315

Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362(24):2251-2259. DOI: https://doi.org/10.1056/NEJMoa0912614

Cortes JE, Gambacorti-Passerini C, Deininger MW, et al. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. J Clin Oncol. 2018;36(3):231-237. DOI: https://doi.org/10.1200/JCO.2017.74.7162

Saussele S, Richter J, Guilhot J, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19(6):747-757. DOI: https://doi.org/10.1016/S1470-2045(18)30192-X

Laneuville P. When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia. Curr Treat Options Oncol. 2018;19(3):15. DOI: https://doi.org/10.1007/s11864-018-0532-2

Kim DDH, Novitzky-Basso I, Kim TS, et al. Optimal duration of imatinib treatment/deep molecular response for treatment-free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial. Br J Haematol. 2021;193(4):779-791. DOI: https://doi.org/10.1111/bjh.17447

Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966-984. DOI: https://doi.org/10.1038/s41375-020-0776-2

Pfirrmann M, Clark RE, Prejzner W, et al. The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia. Leukemia. 2020;34(8):2138-2149. DOI: https://doi.org/10.1038/s41375-020-0931-9

Cortes J. How to manage CML patients with comorbidities. Blood. 2020;136(22):2507-2512. DOI: https://doi.org/10.1182/blood.2020006911

Kantarjian HM, Hughes TP, Larson RA, et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021;35(2):440-453. DOI: https://doi.org/10.1038/s41375-020-01111-2

Haouala A, Widmer N, Duchosal MA, Montemurro M, Buclin T, Decosterd LA. Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood. 2011;117(8):e75-87. DOI: https://doi.org/10.1182/blood-2010-07-294330

Brummendorf TH, Cortes JE, Milojkovic D, et al. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. Leukemia. 2022;36(7):1825-1833. DOI: https://doi.org/10.1038/s41375-022-01589-y

Cortes JE, Apperley JF, DeAngelo DJ, et al. Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review. J Hematol Oncol. 2018;11(1):143. DOI: https://doi.org/10.1186/s13045-018-0685-2

Ong J, Yeung D, Filshie R, Hughes TP, Nandurkar H. Imatinib-induced gastric antral vascular ectasia in three patients with chronic myeloid leukaemia. Int J Hematol. 2015;102(5):639-642. DOI: https://doi.org/10.1007/s12185-015-1824-y

Soverini S, Hochhaus A, Nicolini FE, et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood. 2011;118(5):1208-1215. DOI: https://doi.org/10.1182/blood-2010-12-326405

Issa GC, Kantarjian HM, Gonzalez GN, et al. Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment. Blood. 2017;130(19):2084-2091. DOI: https://doi.org/10.1182/blood-2017-07-792143

Hughes TP, Mauro MJ, Cortes JE, et al. Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. N Engl J Med. 2019;381(24):2315-2326. DOI: https://doi.org/10.1056/NEJMoa1902328



How to Cite

Kim DDH. Tyrosine kinase inhibitors for the frontline management of CML: an overview. Can Hematol Today [Internet]. 2023 Mar. 1 [cited 2023 Sep. 28];2(1):22–26. Available from: https://canadianhematologytoday.com/article/view/2-1-4-kim